Catabolism of extracellular glutathione supplies amino acids to support tumor growth
Hecht, F.; Zocchi, M.; Tuttle, E. T.; Ward, N. P.; Smith, B.; Kang, Y. P.; Cazarin, J.; Soares, Z. G.; Ozgurses, M. E.; Zhao, H.; Sheehan, C.; Alimohammadi, F.; Munger, L. D.; Trivedi, D.; Asantewaa, G.; Blick-Nitko, S. K.; Zoeller, J. J.; Chen, Y.; Vasiliou, V.; Turner, B. M.; Muir, A.; Coloff, J. L.; Munger, J.; DeNicola, G. M.; Harris, I. S.
Show abstract
Restricting amino acids from tumors is an emerging therapeutic strategy with significant promise. While typically considered an intracellular antioxidant with tumor-promoting capabilities, glutathione (GSH) is a tripeptide of cysteine, glutamate, and glycine that can be catabolized, yielding amino acids. The extent to which GSH-derived amino acids are essential to cancers is unclear. Here, we find that GSH catabolism promotes tumor growth. We show that depletion of intracellular GSH does not perturb tumor growth, and extracellular GSH is highly abundant in the tumor microenvironment, highlighting the potential importance of GSH outside of tumors. We find supplementation with GSH can rescue cancer cell survival and growth in cystine-deficient conditions, and this rescue is dependent on the catabolic activity of {gamma}-glutamyltransferases (GGTs). Finally, pharmacologic targeting of GGTs activity prevents the breakdown of circulating GSH, lowers tumor cysteine levels, and slows tumor growth. Our findings indicate a non-canonical role for GSH in supporting tumors by acting as a reservoir of amino acids. Depriving tumors of extracellular GSH or inhibiting its breakdown is potentially a therapeutically tractable approach for patients with cancer. Further, these findings change our view of GSH and how amino acids, including cysteine, are supplied to cells.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A novel non-catalytic scaffolding activity of Hexokinase 2 contributes to EMT and metastasis 97%
- Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM 97%
- Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography 96%
Similar papers in this journal
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 95%
- SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species 95%
- Gut Microbial Trimethylamine is Elevated in Alcohol-Associated Hepatitis and Contributes to Ethanol-Induced Liver Injury in Mice 95%
Similar papers in this journal
- Mitochondrial complex III-derived ROS amplify immunometabolic changes in astrocytes and promote dementia pathology 97%
- Hexokinase detachment from mitochondria drives the Warburg effect to support compartmentalized ATP production 97%
- Autophagy regulator ATG5 preserves cerebellar function by safeguarding its glycolytic activity 95%
Similar papers in this journal
- S-Nitrosylation of CRTC1 in Alzheimer's disease impairs CREB-dependent gene expression induced by neuronal activity 96%
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 96%
- PGC-1a drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.